N/A N=20 Treatment Resistant Depression (Pilot)
Depressive Disorder, Treatment-Resistant
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -9.0; -6.4 Scores on a scale — p=0.53
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=795 Treatment-Resistant Depression Registry
Major Depressive Disorder
Primary: Montgomery Asberg Depression Rating Scale (MADRS)% Responders (>/= 50% Improvement From Baseline) — 24; 8.8; 28; 13.8 Percentage of Participants — p=<.0001
Phase 2 N=104 Efficacy and Tolerability of Riluzole in Treatment Resistant Depression
Depression
Primary: Change in Montgomery and Asberg Depression Rating Scale (MADRS) — 3.20; 5.77; 4.83 units on a scale
Phase 3 N=13 Buprenorphine for Treatment Resistant Depression
Depression · Depressive Disorder · Depressive Disorder, Major
Primary: Montgomery Asberg Depression Rating Scale — 33.8; 32.6 units on a scale
N/A N=10 Augmentation of Treatment-Resistant Depression With An Analog of the Neuroactive Steroid Allopregnanolone
Major Depressive Disorder
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) — 12.8 units on a scale
Phase 3 N=688 Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients
Major Depressive Disorder · Treatment Resistant Depression
Primary: Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Per Protocol Analysis…
Phase 4 N=619 Optimizing Outcomes of Treatment-Resistant Depression in Older Adults
Treatment Resistant Depression · Major Depressive Disorder · Treatment-Refractory Depression
Primary: Psychological Well-Being — 34.7; 35.0; 34.8; 33.1 t-score — p=0.010
N/A N=12 rTMS in Treatment Resistant Depression
Depression
Primary: Depression Severity as Assessed by the Montgomery Åsberg Depression Rating Scale (MADRS) Score — 26.4; 29.29; 11.5; 16.3 units on a scale
Phase 3 N=325 Study In Patients With Depression Not Responding to Selective Serotonin Re-uptake Inhibitors
Depressive Disorder
Primary: Change From Baseline in the Hamilton Depression Scale (HAM-D 17 Items) Total Score — 19.8; 19.4; 14.7; 14.6 Score in scale — p=0.805
N/A N=5 Deep Brain Stimulation (DBS) for Treatment-Resistant Depression (TRD)
Treatment Resistant Depression · Depressive Disorder, Treatment-Resistant · Depression, Bipolar
Primary: Comparison of 12 Weeks of Left Unilateral DBS vs. 12 Weeks Right Unilateral DBS on Change in 17-item Hamilton Depression Rating Scale (HDRS-17) — 22.35; 18.8; 21.4; 17.4…
Phase 2 N=20 Nuedexta in Treatment-Resistant Major Depression
Major Depressive Disorder · Treatment Resistant
Primary: Montgomery-Asberg Depression Rating Scale — -13.0 change in units on a scale
N/A N=14 Ketamine Infusion for Treatment-resistant Major Depressive Disorder
Major Depressive Disorder
Primary: Response to Ketamine as Measured by Hamilton Depression Rating Scale -28 Items (HAMD28) — 5 participants who met response criteria
Phase 2 N=248 Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression
Treatment Resistant Depression
Primary: Change From Baseline to Week 4 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. — -12.2; -11.6 units on a scale — p=0.7941
N/A N=40 Accelerated Theta Burst in Treatment-Resistant Depression: A Dose Finding and Biomarker Study
Treatment Resistant Depression
Primary: Change in Hamilton Depression Rating Scale 21-Item Score — 23.51; 9.44 score on a scale
N/A N=31 Mifepristone in Refractory Depression
Depression
Primary: Hamilton Depression Rating Scale — 18.75; 19.68 units on a scale — p=<.26
Phase 2 N=197 A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD
Treatment Resistant Depression
Primary: Change in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score From Baseline to Day 42, in DGM4-positive Patients — -15.4; -15.5; -15.4; -11.0 Units on a Scale…
Phase 3 N=892 A Study in Relapse Prevention of Treatment-Resistant Depression
Treatment Resistant Depression
Primary: Time to Relapse by Any Criteria — NA; NA days — p=<0.001
Phase 2 N=73 Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression
Depression
Primary: Hamilton Depression Rating Scale Remission Rates — 46.1; 17.6 Percentage of Remitters HDRS17
Phase 3 N=227 A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
Treatment-resistant Depression
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 in the Double-blind Induction Phase- Mixed-Effects Model Using…
Phase 3 N=346 A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
Treatment-resistant Depression
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 of Double- Blind Induction Phase- Mixed- Effects Model Using Repeated…
Phase 4 N=51 A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)
Depression
Primary: Change From Baseline on Symptoms of Depression Questionnaire (SDQ) — 3.7; 3.7; 3.5; 3.5 score on a scale — p=0.46
Phase 1 N=13 KET-RO Plus RO DBT for Treatment Resistant Depression
Treatment Resistant Depression
Primary: Decrease in Depressive Symptoms — 12.13 Score on MADRS — p=0.0065
Phase 2 N=30 Reclaim Deep Brain Stimulation Clinical Study for Treatment-Resistant Depression
Depression
Primary: Responders — 3; 2 participants — p==0.53
Phase 4 N=181 Incomplete Response in Late Life Depression: Getting to Remission (IRL GREY)
Depression
Primary: Percentage of Subjects Who Met Criteria for Remission Based on the Montgomery-Asberg Depression Rating Scale (MADRS) — 44; 29 percentage of participants
Phase 2 N=5 Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients
Treatment Resistant Depression
Primary: Cortical Excitability in the Dorsolateral Prefrontal Cortex (DLPFC) as Assessed by Transcranial Magnetic Stimulation-evoked Activity Detected by Electroencephalography…
Phase 2 N=7 Targeting IL-17A for Treatment-Resistant Depression
Major Depressive Disorder
Primary: Number of Participants Who Dropped-out — 0 Participants
Phase 2 N=34 Ketamine Plus Lithium in Treatment-Resistant Depression
Depression
Primary: MADRS-S Score — 22.56; 23 units on a scale
Phase 4 N=477 A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
Depressive Disorder, Treatment-Resistant
Primary: Double-blind Treatment Phase: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Day 1 (Pre-randomization) to Day 28 — -7.0; -12.7; -13.9 Score…
Phase 3 N=150 TRIAD - Treatment of Insomnia and Depression
Sleep Initiation and Maintenance Disorders · Depression
Primary: Percent of Participants With Depression Remission — 36.0; 43.8 percentage of participants in arm
N/A N=20 Intranasal Ketamine in Treatment-Resistant Depression
Major Depressive Disorder
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) — 8; 1 participants — p=<0.001